Scinai Immunotherapeutics Management
Management criteria checks 3/4
Scinai Immunotherapeutics' CEO is Amir Reichman, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is $927.00K, comprised of 56.1% salary and 43.9% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth €7.73K. The average tenure of the management team and the board of directors is 4.5 years and 4.8 years respectively.
Key information
Amir Reichman
Chief executive officer
US$927.0k
Total compensation
| CEO salary percentage | 56.1% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4.5yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$5m |
| Jun 30 2024 | n/a | n/a | -US$4m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$927k | US$520k | -US$6m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$7m |
| Dec 31 2022 | US$1m | US$368k | -US$6m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$1m | US$664k | -US$8m |
Compensation vs Market: Amir's total compensation ($USD927.00K) is above average for companies of similar size in the German market ($USD468.04K).
Compensation vs Earnings: Amir's compensation has been consistent with company performance over the past year.
CEO
Amir Reichman (48 yo)
3.8yrs
Tenure
US$927,000
Compensation
Mr. Amir Reichman M.Sc, M.B.A, has been the Chief Executive Officer at Scinai Immunotherapeutics Ltd. (formerly known as BiondVax Pharmaceuticals Ltd.) since March 02, 2021 and has been its Director since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$927.00k | 0.28% € 7.7k | |
| Chief Financial Officer | 17.9yrs | US$174.00k | no data | |
| Chief Operating Officer | 5.3yrs | US$265.00k | no data | |
| Chief Technology Officer | less than a year | US$232.00k | no data | |
| Chief Scientist | 20.9yrs | US$297.00k | no data | |
| Head of Business Development & Sales | less than a year | no data | no data | |
| Head of Quality Control | no data | no data | no data |
4.5yrs
Average Tenure
53yo
Average Age
Experienced Management: 2F5's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.8yrs | US$927.00k | 0.28% € 7.7k | |
| Independent Director | 4.8yrs | US$92.19k | 0.0039% € 106.4 | |
| Independent Director | 7.1yrs | US$78.79k | 0.0039% € 106.4 | |
| Independent Director | 4.8yrs | US$87.02k | 0.0039% € 106.4 | |
| Chairman of the Board | 6.5yrs | US$336.67k | no data | |
| Head of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | US$68.36k | no data | |
| Independent Director | 2.9yrs | US$76.59k | 0.0080% € 219.1 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 4.8yrs | US$493.15k | no data | |
| Independent Director | 3yrs | US$72.36k | 0.0025% € 67.6 | |
| Member of Scientific Advisory Board | 2yrs | no data | no data |
4.8yrs
Average Tenure
71yo
Average Age
Experienced Board: 2F5's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 03:15 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Scinai Immunotherapeutics Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |